Anavex Life Sciences Corp (AVXL)

[georgejjl]

Supplementary Figure 4: Exceptional therapeutic response Longitudinal change in MMSE and ADCS-ADL over 148 weeks of combined studies of two patients (a and b) having SIGMAR1 gene wild type, mean high concentration levels of ANAVEX2-73 in plasma in Part B and baseline MMSE ≥20. All n=6 subjects, including patients a and b, with these response characteristics are shown in Figure 3.

An additional ten patients had “unexpected positive benefit” described by their investigator in the CRF data e.g. improved mood, increase attention, improved sleep. Eight of these patients recorded a high ANAVEX2-73 plasma concentration (≥4.0ng/ml) in Part B.

https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/trc2.12013

Good luck and GOD bless,